Actual and potential agents and biomarkers in the treatment of cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 500-516

  Carrera, M P ^a   Ramirez Exposito M J ^a   Martinez Martos J M ^a  

^a UNIVERSITY OF JAÉN   (Spain)

Author keywords

Cancer; Chemotherapy; Natural compounds; Oxidative stress; Renin angiotensin system

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBOXYPEPTIDASE; CARMUSTINE; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPHOS; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; GONADORELIN AGONIST; IDARUBICIN; IRINOTECAN; MELATONIN; NITROSOUREA DERIVATIVE; OLEIC ACID; OLIVE OIL; PACLITAXEL; PEMETREXED; PHENOL DERIVATIVE; PYRROLIDONE CARBOXYPEPTIDASE; RESVERATROL; RETINOID DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; CYTOTOXICITY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DOWN REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HEARING LOSS; HEART FAILURE; HEART INJURY; HODGKIN DISEASE; HUMAN; HYPOMAGNESEMIA; IMMUNOMODULATION; IMMUNOSTIMULATION; KAPOSI SARCOMA; LARYNX CANCER; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACOLOGICAL BLOCKING; PYRIDOXINE DEFICIENCY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMATITIS; TESTIS CANCER; TETANY; THROMBOCYTOPENIA; TINNITUS; UROGENITAL TRACT CANCER; VOMITING;

EID: 67651094221     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788451824     Document Type: Review

References (236)

1. Gerber, D.E. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician, 2008, 77(3), 311-9.
2. American Cancer Society (ACS). www.cancer.org
3. Peyrone M. Ann. Chemie. Pharm., 1845, 51, 1-29.
4. Rosenberg, B.; Vancamp, L.; Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698-9.
5. Timmer-Bosscha, H.; Mulder, N.H.; de Vries, E.G. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br. J. Cancer, 1992, 66(2), 227-38.
6. Chu, G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem., 1994, 269(2), 787-90.
7. Perez, R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer, 1998, 34(10), 1535-42.
8. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 1990, 2(8-9), 275-80.
9. Hayakawa, J.; Ohmichi, M.; Kurachi, H.; Ikegami, H.; Kimura, A.; Matsuoka, T.; Jikihara, H.; Mercola, D.; Murata, Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J. Biol. Chem., 1999, 274(44), 31648-54.
10. Persons, D.L.; Yazlovitskaya, E.M.; Cui, W.; Pelling, J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res., 1999, 5(5), 1007-14.
11. Gao, X.S.; Asaumi, J.; Kawasaki, S.; Nishikawa, K.; Kuroda, M.; Takeda, Y.; Hiraki, Y.; Ihara, M.; Ohnishi, T. Sensitivity of anticancer drugs in NIH3T3' cells transfected with oncogenes accompanied by pSV2neo vector. Anticancer Res., 1995, 15(5B), 1911-4.
12. Fokstuen, T.; Rabo, Y.B.; Zhou, J.N.; Karlson, J.; Platz, A.; Shoshan, M.C.; Hansson, J.; Linder, S. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line. Anticancer Res., 1997, 17(4A), 2347-52.
13. Wang, X.; Martindale, J.L.; Holbrook, N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem., 2000, 275(50), 39435-43.
14. Von Hoff, D.D.; Schilsky, R.; Reichert, C.M.; Reddick, R.L.; Rozencweig, M.; Young, R.C.; Muggia, F.M. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat. Rep., 1979, 63(9-10), 1527-31.
15. Kociba, R.J.; Sleight, S.D. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep., 1971, 55(1), 1-8.
16. Ozols, R.F.; Deisseroth, A.B.; Javadpour, N.; Barlock, A.; Messerschmidt, G.L.; Young, R.C. Treatment of poor prognosis nonseminomatous testicular cancer with a "high-dose" platinum combination chemotherapy regimen. Cancer, 1983, 51(10), 1803-7.
17. Stadnicki, S.W.; Fleischman, R.W.; Schaeppi, U.; Merriam, P. Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother. Rep., 1975, 59(3), 467-80.
18. Ravi, R.; Somani, S.M.; Rybak, L.P. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol. Toxicol., 1995, 76(6), 386-94.
19. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-96.
20. Reardon, D.A.; Wen, P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, 2006, 11(2), 152-64.
21. Tentori, L.; Orlando, L.; Lacal, P.M.; Benincasa, E.; Faraoni, I.; Bonmassar, E.; D'Atri, S.; Graziani, G. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol. Pharmacol., 1997, 52(2), 249-58.
22. Park, J.A.; Joe, Y.A.; Kim, T.G.; Hong, Y.K. Potentiation of antiglioma effect with combined temozolomide and interferon-beta. Oncol. Rep., 2006, 16(6), 1253-60.
23. Kanzawa, T.; Bedwell, J.; Kondo, Y.; Kondo, S.; Germano, I.M. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg., 2003, 99(6), 1047-52.
24. Kanzawa, T.; Germano, I.M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ., 2004, 11(4), 448-57.
25. Roos, W.P.; Batista, L.F.; Naumann, S.C.; Wick, W.; Weller, M.; Menck, C.F.; Kaina, B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene, 2007, 26(2), 186-97.
26. Maiuri, M.C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell. Biol., 2007, 8(9), 741-52.
27. Bocangel, D.B.; Finkelstein, S.; Schold, S.C.; Bhakat, K.K.; Mitra, S.; Kokkinakis, D.M. Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res., 2002, 8(8), 2725-34.
28. Liu, L.; Markowitz, S.; Gerson, S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res., 1996, 56(23), 5375-9.
29. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343(19), 1350-4.
30. Hegi, M.E.; Diserens, A.C.; Godard, S.; Dietrich, P.Y.; Regli, L.; Ostermann, S.; Otten, P.; Van Melle, G.; de Tribolet, N.; Stupp, R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res., 2004, 10(6), 1871-4.
31. Ochs, K.; Kaina, B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res., 2000, 60(20), 5815-24.
32. Weller, M.; Steinbach, J.P.; Wick, W. Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncol., 2005, 1(6), 747-54.
33. Beranek, D.T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res., 1990, 231(1), 11-30.
34. Kaina, B.; Fritz, G.; Mitra, S.; Coquerelle, T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis, 1991, 12(10), 1857-67.
35. Ludlum, D.B. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest., 1997, 15(6), 588-98.
36. Bacolod, M.D.; Johnson, S.P.; Pegg, A.E.; Dolan, M.E.; Moschel, R.C.; Bullock, N.S.; Fang, Q.; Colvin, O.M.; Modrich, P.; Bigner, D.D.; Friedman, H.S. Brain tumor cell lines resistant to O6-benzylguanine/1, 3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol. Cancer Ther., 2004, 3(9), 1127-35.
37. Fischhaber, P.L.; Gall, A.S.; Duncan, J.A.; Hopkins, P.B. Direct demonstration in synthetic oligonucleotides that N,N'-bis(2-chloroethyl)-nitrosourea cross links N1 of deoxyguanosine to N3 of deoxycytidine on opposite strands of duplex DNA. Cancer Res., 1999, 59(17), 4363-8.
38. Batista, L.F.; Roos, W.P.; Christmann, M.; Menck, C.F.;Kaina, B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating Anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res., 2007, 67(24), 11886-95.
39. Rabik, C.A.; Njoku, M.C.; Dolan, M.E. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev., 2006, 32(4), 261-76.
40. Becker, K.; Schirmer, R.H. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. Methods Enzymol., 1995, 251, 173-88.
41. Council M.R. Randomized trial of procarbazine, lomustina, and vincristina in the adyuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J. Clin. Oncol., 2001, 19(2), 509-18.
42. Bokstein, F.; Kovner, F.; Blumenthal, D.T.; Ram, Z.; Templehoff, H.; Kanner, A.A.; Corn, B.W. A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72(3), 900-904.
43. Cao, T.M.; Negrin, R.S.; Stockerl-Goldstein, K.E.; Johnston, L.J.; Shizuru, J.A.; Taylor, T.L.; Rizk, N.W.; Wong, R.M.; Blume, K.G.; Hu, W.W. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant., 2000, 6(4), 387-94.
44. Stahl, W.; Lenhardt, S.; Przybylski, M.; Eisenbrand, G. Mechanism of glutathione-mediated DNA damage by the antineoplastic agent 1,3-bis(2-chloroethyl)-N-nitrosourea. Chem. Res. Toxicol., 1992, 5(1), 106-9.
45. McKendrick, J.; Coutsouvelis, J. Capecitabine: effective oral fluoropyrimidine chemotherapy. Expert. Opin. Pharmacother., 2005, 6(7), 1231-9.
46. Walko, C.M.; Lindley, C. Capecitabine: a review. Clin. Ther., 2005, 27(1), 23-44.
47. Ben-Josef, E. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. Am. J. Clin. Oncol., 2007, 30 (6), 649-55.
48. Hoff, P.M.; Cassidy, J.; Schmoll, H.J. The evolution of fluoropyrimidine therapy: from intravenous to oral. Oncologist, 2001, 6, 3-11.
49. Hanna, N.; Shepherd, F.A.; Fossella, F.V.; Pereira, J.R.; De Marinis, F.; von Pawel, J.; Gatzemeier, U.; Tsao, T.C.; Pless, M.; Muller, T.; Lim, H.L.; Desch, C.; Szondy, K.; Gervais, R.; Shaharyar; Manegold, C.; Paul, S.; Paoletti, P.; Einhorn, L.; Bunn, P.A. Jr Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol., 2004, 22(9), 1589-97.
50. Shih, C.; Habeck, L.L.; Mendelsohn, L.G.; Chen, V.J.; Schultz, R.M. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine- based antifolate LY231514 (MTA). Adv. Enzyme Regul., 1998, 38, 135-52.
51. Hanauske, A.R.; Chen, V.; Paoletti, P.; Niyikiza, C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist, 2001, 6(4), 363-73.
52. Laohavinij, S.; Wedge, S.R.; Lind, M.J.; Bailey, N.; Humphreys, A.; Proctor, M.; Chapman, F.; Simmons, D.; Oakley, A.; Robson, L.; Gumbrell, L.; Taylor, G.A.; Thomas, H.D.; Boddy, A.V.; Newell, D.R.; Calvert, A.H. A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest. N. Drugs, 1996, 14(3), 325-35.
53. Niyikiza, C.; Baker, S.D.; Seitz, D.E.; Walling, J.M.; Nelson, K.; Rusthoven, J.J.; Stabler, S.P.; Paoletti, P.; Calvert, A.H.; Allen, R.H. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther., 2002, 1(7), 545-52.
54. Stinchcombe, T.E.; Socinski, M.A. Considerations for second-line therapy of non-small cell lung cancer. Oncologist, 2008, 13(9), 28-36.
55. Tewey, K.M.; Rowe, T.C.; Yang, L.; Halligan, B.D.; Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian topoisomerase II. Science, 1984, 226(4673): 446-8.
56. Bachur, N.R.; Yu, F.; Johnson, R.; Hickey, R.; Wu, Y.; Malkas, L. Helicase inhibition by anthracycline Anticancer agents. Mol. Pharmacol., 1992, 41(6), 993-8.
57. Myers, C.E.; McGuire, W.P.; Liss, R.H.; Ifrim, I.; Grotzinger, K.; Young, R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science, 1977, 197(4299), 165-7.
58. Minotti, G. Adriamycin-dependent release of iron from microsomal membranes. Arch. Biochem. Biophys., 1989, 268(1), 398-403.
59. Hande, K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer, 1998, 34(10), 1514-21
60. Rahman, A.M.; Yusuf, S.W.; Ewer, M.S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomed., 2007, 2(4), 567-83.
61. Steinherz, L.J.; Steinherz, P.G.; Tan, C.T.; Heller, G.; Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991, 266(12), 1672-7.
62. Swain, S.M.; Whaley, F.S.; Gerber, M.C.; Weisberg, S.; York, M.; Spicer, D.; Jones, S.E.; Wadler, S.; Desai, A.; Vogel, C.; Speyer, J.; Mittelman, A.; Reddy, S.; Pendergrass, K.; Velez-Garcia, E.; Ewer, M.S.; Bianchine, J.R.; Gams, R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol., 1997, 15(4), 1318-32.
63. Elliott, P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol., 2006, 33(3), S2-7.
64. Goebel, F.D.; Goldstein, D.; Goos, M.; Jablonowski, H.; Stewart, J.S. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group. Br. J. Cancer, 1996, 73(10), 989-94.
65. Berman, E. A review of idarubicin in acute leukemia. Oncology (Williston Park), 1993, 7(10), 91-8, 104.
66. Feig, S.A.; Ames, M.M.; SaTher., H.N.; Steinherz, L.; Reid, J.M.; Trigg, M.; Pendergrass, T.W.; Warkentin, P.; Gerber, M.; Leonard, M.; Bleyer, W.A.; Harris, R.E. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med. Pediatr. Oncol., 1996, 27(6), 505-14.
67. Lasota, W.S.; de Valeriola, D.L.; Piccart, M.J. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging, 1994, 4(5), 392-402.
68. Wall, M.E.; Wani, M.C.; Cook, C.; Palmer, K.H.; MacPhail, A.T.; Sim, G.A. Plant antitumor agents, 1. Isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor form campototheca acuminate. J. Am. Chem., 1966, 88(16), 3888-3890.
69. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; Liu, L.F. Camptothecin induces protein-linked DNA breaks via. mammalian DNA topoisomerase I. J. Biol. Chem., 1985, 260, 14873-8.
70. Gallo, R.C.; Whang-Peng, J.; Adamson, R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst., 1971, 46(4), 789-95.
71. Schaeppi, U.; Fleischman, R.W.; Cooney, D.A. Toxicity of camptothecin (NSC-100880). Cancer Chemother. Rep., 1974, 5(1), 25-36.
72. Gottlieb, J.A.; Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 1972, 56(1), 103-5.
73. Moertel, C.G.; Schutt, A.J.; Reitemeier, R.J.; Hahn, R.G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 1972, 56(1), 95-101.
74. Kunimoto, T.; Nitta, K.; Tanaka, T.; Uehara, N.; Baba, H.; Takeuchi, M.; Yokokura, T.; Sawada, S.; Miyasaka, T.; Mutai, M. Antitumor activity of 7-ethyl-10-4-(1-piperidino)-1-piperidinocarbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 1987, 47(22), 5944-7.
75. Matsuzaki, T.; Yokokura, T.; Mutai, M.; Tsuruo, T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother. Pharmacol., 1988, 21(4), 308-12.
76. Tsuruo, T.; Matsuzaki, T.; Matsushita, M.; Saito, H.; Yokokura, T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother. Pharmacol., 1988, 21(1), 71-4.
77. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 1991, 51(16), 4187-91.
78. Sandmeier, D.; Chaubert, P.; Bouzourene, H. Irinotecan-induced colitis. Int. J. Surg. Pathol., 2005, 13(2), 215-8.
79. Expósito, O.; Bonfill, M.; Moyano, E.; Onrubia, M.; Mirjalili, M.H.; Cusidó, R.M.; Palazón, J. Biotechnological production of taxol and related taxoids: current state and prospects. Anticancer Agents Med. Chem., 2009, 9(1), 109-21.
80. Crown, J.; O'Leary, M. The taxanes: an update. Lancet, 2000, 355(9210), 1176-8.
81. Noble, R.L. The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochem. Cell. Biol., 1990, 68(12), 1344-51.
82. Sathornsumetee, S.; Reardon, D.A.; Desjardins, A.; Quinn, J.A.; Vredenburgh, J.J.; Rich, J.N. Molecularly targeted therapy for malignant glioma. Cancer, 2007, 110(1), 13-24.
83. Goldbrunner, R.H.; Bendszus, M.; Wood, J.; Kiderlen, M.; Sasaki, M.; Tonn, J.C. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery, 2004, 55(2), 426-32.
84. Kilic, T.; Alberta, J.A.; Zdunek, P.R.; Acar, M.; Iannarelli, P.; O'Reilly, T.; Buchdunger, E.; Black, P.M.; Stiles, C.D. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res., 2000, 60(18), 5143-50.
85. Geng, L.; Shinohara, E.T.; Kim, D.; Tan, J.; Osusky, K.; Shyr, Y.; Hallahan, D.E. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys., 2006, 64(1), 263-71.
86. Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.M.; Muzikansky, A.; Loeffler J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22(10),1926-33.
87. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441(7092), 424-30.
88. Momota, H.; Nerio, E.; Holland, E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res., 2005, 65(16), 7429-35.
89. Santen, R.J.; Lipton, A.; Kendall, J. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA, 1974, 230(12), 1661-5.
90. Altundag, K.; Ibrahim, N.K. Aromatase inhibitors in breast cancer: an overview. Oncologist, 2006, 11(6), 553-62.
91. Hong, Y.; Chen, S. Aromatase inhibitors: structural features and biochemical characterization. Ann. N. Y. Acad. Sci., 2006, 1089, 237-51.
92. Ponzone, R.; Mininanni, P.; Cassina, E.; Pastorino, F.; Sismondi, P. Aromatase inhibitors for breast cancer: different structuRes., same effects? Endocr. Relat. Cancer, 2008, 15(1), 27-36.
93. Cuzick, J.; Ambroisine, L.; Davidson, N.; Jakesz, R.; Kaufmann, M.; Regan, M.; Sainsbury, R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet, 2007, 369(9574), 1711-23.
94. Kurebayashi, J. Adjuvant therapy for premenopausal patients with early breast cancer. Curr. Opin. Obstet. Gynecol., 2008, 20(1), 51-4.
95. Urruticoechea, A. The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective. Clin. Transl. Oncol., 2007, 9(12), 752-9.
96. Paul, B.; Masih, I.; Deopujari, J.; Charpentier, C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J. Ethnopharmacol., 1999, 68(1-3), 71-6.
97. Vastano, B.C.; Chen, Y.; Zhu, N.; Ho, C.T.; Zhou, Z.; Rosen, R.T. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. Food Chem., 2000, 48(2), 253-6.
98. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275(5297), 218-20.
99. Pezzuto, J.M. Plant-derived Anticancer agents. Biochem. Pharmacol., 1997, 53(2), 121-33.
100. Das, D.K.; Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., 2006, 6(1), 36-47.
101. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.;Kim, A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224(3), 274-83.
102. Bhat, K.P.; Lantvit, D.; Christov, K.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 2001, 61(20), 7456-63.
103. Serrero, G.; Lu, R. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid. Redox. Signal., 2001, 3(6), 969-79.
104. Magee, P.J.; Rowland, I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr., 2004, 91(4), 513-31.
105. Pozo-Guisado, E.; Lorenzo-Benayas, M.J.; Fernandez-Salguero, P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int. J. Cancer, 2004, 109(2), 167-73.
106. El-Mowafy, A.M.; Alkhalaf, M. Resveratrol activates adenylylcyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis, 2003, 24(5), 869-73.
107. Scarlatti, F.; Sala, G.; Somenzi, G.; Signorelli, P.; Sacchi, N.; Ghidoni, R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via. de novo ceramide signaling. FASEB J., 2003, 17(15), 2339-41.
108. Bianco, N.R.; Chaplin, L.J.;Montano, M.M. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J., 2005, 385(1), 279-87.
109. Pozo-Guisado, E.; Merino, J.M.; Mulero-Navarro, S.; Lorenzo-Benayas, M.J.; Centeno, F.; Alvarez-Barrientos, A.; Fernandez-Salguero, P.M. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int. J. Cancer, 2005, 115(1), 74-84.
110. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5(3), 621-9.
111. Bhat, K.P.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci., 2002, 957, 210-29.
112. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62, 4945-54.
113. Whitsett, T.; Carpenter, M.; Lamartiniere, C.A. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinog., 2006, 5, 15.
114. Sato, M.; Pei, R.J.; Yuri, T.; Danbara, N.; Nakane, Y.; Tsubura, A. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett., 2003, 202(3), 137-45.
115. Russo, J.; Russo, I.H. Biological and molecular bases of mammary carcinogenesis. Lab. Invest., 1987, 57(2), 112-37.
116. Seve, M.; Chimienti, F.; Devergnas, S.; Aouffen, M.; Douki, T.; Chantegrel, J.; Cadet, J.; Favier, A. Resveratrol enhances UVA-induced DNA damage in HaCaT human keratinocytes. Med. Chem., 2005, 1(6),629-33.
117. Bubenik, G.A. Gastrointest.nal melatonin: localization, function, and clinical relevance. Dig. Dis. Sci, 2002, 47(10), 2336-48.
118. Hardeland, R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 2005, 27(2), 119-30.
119. Murch, S.J.; Simmons, C.B.; Saxena, P.K. Melatonin in feverfew and other medicinal plants. Lancet, 1997, 350(9091), 1598-9.
120. Karasek, M.; Reiter, R.J.; Cardinali, D.P.; Pawlikowski, M. Future of melatonin as a therapeutic agent. Neuro. Endocrinol. Lett., 2002, 23, 118-21.
121. Manchester, L.C.; Tan, D.X.; Reiter, R.J.; Park, W.; Monis, K.; Qi, W. High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci., 2000, 67(25), 3023-9.
122. Burkhardt, S.; Tan, D.X.; Manchester, L.C.; Hardeland, R.; Reiter, R.J. Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus). J. Agric. Food Chem., 2001, 49(10), 4898-902.
123. Tan, D.X.; Manchester, L.C.; Hardeland, R.; Lopez-Burillo, S.; Mayo, J.C.; Sainz, R.M.; Reiter, R.J. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J. Pineal. Res., 2003, 34(1), 75-8.
124. Lissoni, P.; Esposti, D.; Esposti, G.; Mauri, R.; Resentini, M.; Morabito, F.; Fumagalli, P.; Santagostino, A.; Delitala, G.; Fraschini, F. A clinical study on the relationship between the pineal gland and the opioid system. J. Neural. Transm., 1986, 65(1), 63-73.
125. Carrillo-Vico, A.; Guerrero, J.M.; Lardone, P.J.; Reiter, R.J. A review of the multiple actions of melatonin on the immune system. Endocrine, 2005, 27(2), 189-200.
126. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.; Cardinali, D.P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature's most versatile biological signal? FEBS J., 2006, 273(13), 2813-38.
127. Lissoni, P.; Barni, S.; Ardizzoia, A.; Tancini, G.; Conti, A.; Maestroni, G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer, 1994, 73(3), 699-701.
128. Lissoni, P.; Brivio, O.; Brivio, F.; Barni, S.; Tancini, G.; Crippa, D.; Meregalli, S. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J. Pineal. Res., 1996, 21(4), 239-42.
129. Blask, D.E.; Sauer, L.A.; Dauchy, R.T. Melatonin as a chronobiotic/ Anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Top. Med. Chem., 2002, 2(2), 113-32.
130. Blask, D.E.; Brainard, G.C.; Dauchy, R.T.; Hanifin, J.P.; Davidson, L.K.; Krause, J.A.; Sauer, L.A.; Rivera-Bermudez, M.A.; Dubocovich, M.L.; Jasser, S.A.; Lynch, D.T.; Rollag, M.D.; Zalatan, F. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res., 2005, 65(23), 11174-84.
131. Riabykh, T.P.; Nikolaeva, T.G.; Bodrova, N.B. Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors. Vestn. Ross. Akad. Med. Nauk, 2000, 8, 30-3.
132. Blask, D.E.; Wilson, S.T; Zalatan, F. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res., 1997, 57(10), 1909-14.
133. Moretti, R.M.; Marelli, M.M.; Maggi, R.; Dondi, D.; Motta, M.; Limonta, P. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol. Rep., 2000, 7(2), 347-51.
134. Cini, G.; Coronnello, M.; Mini, E.; Neri, B. Melatonin's growthinhibitory effect on hepatoma AH 130 in the rat. Cancer Lett., 1998, 125(1-2), 51-9.
135. Shiu, S.Y.; Li, L.; Xu, J.N.; Pang, C.S.; Wong, J.T.; Pang, S.F. Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J. Pineal. Res., 1999, 27(3), 183-92.
136. Cos, S.; Sanchez-Barcelo, E.J. Melatonin and mammary pathological growth. Front Neuroendocrinol., 2000, 21(2), 133-70.
137. Poeggeler, B.; Thuermann, S.; Dose, A.; Schoenke, M.; Burkhardt, S.; Hardeland, R. Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal. Res., 2002, 33(1), 20-30.
138. Anisimov, V.N. Life span extension and cancer risk: myths and reality. Exp. Gerontol., 2001, 36(7), 1101-36.
139. Winczyk, K.; Pawlikowski, M.; Karasek, M. Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J. Pineal. Res., 2001, 31(2), 179-82.
140. Ubeda, A.; Trillo, M.A.; House, D.E.; Blackman, C.F. Melatonin enhances junctional transfer in normal C3H/10T1/2 cells. Cancer Lett., 1995, 91(2), 241-5.
141. Roth, J.A.; Kim, B.G.; Lin, W.L.; Cho, M.I. Melatonin promotes osteoblast differentiation and bone formation. J. Biol. Chem., 1999, 274(31), 22041-7.
142. Maestroni, G.J.; Conti, A. Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab. Invest., 1996, 75(4), 557-61.
143. Rato, A.G.; Pedrero, J.G.; Martinez, M.A.; del Rio, B.; Lazo, P.S.; Ramos, S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J., 1999, 13(8), 857-68.
144. Hill, S.M.; Collins, A.; Kiefer, T.L. The modulation of oestrogen receptor-alpha activity by melatonin in MCF-7 human breast cancer cells. Eur. J. Cancer, 2000, 36(4), 117-8.
145. Guerrero, J.M.; Reiter, R.J. Melatonin-immune system relationships. Curr. Top. Med. Chem., 2002, 2(2), 167-79.
146. Mayo, J.C.; Sainz, R.M.; Tan, D.X.; Hardeland, R.; Leon, J.; Rodriguez, C.; Reiter, R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol., 2005, 165(1-2), 139-49.
147. Reiter, R.J.; Tan, D.X.; Sainz, R.M.; Mayo, J.C. Melatonin protects the heart against both ischemia/reperfusion injury and chemotherapeutic drugs. Cardiovasc. Drugs Ther., 2002, 16(1), 5-6.
148. Reiter, R.J.; Tan, D.X.; Sainz, R.M.; Mayo, J.C.; Lopez-Burillo, S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol., 2002, 54(10), 1299-321.
149. Vijayalaxmi, Thomas, C.R. Jr; Reiter, R.J.; Herman, T.S. Melatonin: from basic research to cancer treatment clinics. J. Clin. Oncol., 2002, 20(10), 2575-601.
150. Futagami, M.; Sato, S.; Sakamoto, T.; Yokoyama, Y.; Saito, Y. Effects of melatonin on the proliferation and cisdiamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells. Gynecol. Oncol., 2001, 82(3), 544-9.
151. Lissoni, P.; Paolorossi, F.; Ardizzoia, A.; Barni, S.; Chilelli, M.; Mancuso, M.; Tancini, G.; Conti, A.; Maestroni, G.J. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal. Res., 1997, 23(1), 15-9.
152. Cos, S.; Gonzalez, A.; Guezmes, A.; Mediavilla, M.D.; Martinez-Campa, C.; Alonso-Gonzalez, C.; Sanchez-Barcelo, E.J. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer, 2006, 118(2), 274-8.
153. Lotan, R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst., 1995, 87(2), 1655-7.
154. Liu, H.; Zang, C.; Fenner, M.H.; Possinger, K.; Elstner, E. PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res. Treat., 2003, 79(1), 63-74.
155. Wu, Q.; Zhang, M.; Liu, S.; Chen, Y.; Su, W. Retinoic acid receptor beta is required for anti-activator protein-1 activity by retinoic acid in gastric cancer cells. Chin. Med. J. (Engl.), 2002, 115(6), 810-4.
156. Adachi, Y.; Itoh, F.; Yamamoto, H.; Iku, S.; Matsuno, K.; Arimura, Y.; Imai, K; Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol., 2001, 22(4), 247-53.
157. Garcia-Alonso, I.; PalomaRes., T.; Alonso-Varona, A.; Castro, B.; Del Olmo, M.; Portugal, V.; Mendez, J. Effects of all-trans retinoic acid on tumor recurrence and metastasis. Rev. Esp. Enferm. Dig, 2005, 97(4), 240-8.
158. Heukamp, I.; Kilian, M.; Gregor, J.I.; Neumann, A.; Jacobi, C.A.; Guski, H.; Schimke, I.; Walz, M.K.; Wenger, F.A. Effects of the antioxidative vitamins A, C and E on liver metastasis and intrametastatic lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology, 2005, 5(4-5), 403-9.
159. Day, R.M.; Lee, Y.H.; Park, A.M.; Suzuki, Y.J. Retinoic acid inhibits airway smooth muscle cell migration. Am. J. Respir. Cell. Mol. Biol., 2006, 34(6), 695-703.
160. Park, E.Y.; Wilder, E.T.; Lane, M.A. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr. Cancer, 2007, 57(1), 66-77.
161. Park, E.Y.; Wilder, E.T.; Chipuk, J.E.; Lane, M.A. Retinol decreases phosphatidylinositol 3-kinase activity in colon cancer cells. Mol. Carcinog., 2008, 47(4), 264-74.
162. West, K.A.; Castillo, S.S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 2002, 5(6), 234-48.
163. Lotan, R. Retinoids in cancer chemoprevention. FASEB J., 1996, 10(9), 1031-9.
164. Melancon, K.; Cheng, Q.; Kiefer, T.L.; Dai, J.; Lai, L.; Dong, C.; Yuan, L.; Collins, A.; Thiyagarajah, A.; Long, S.; Hill, S.M. Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett., 2005, 227(1), 39-48.
165. Gilani, A.H.; Khan, A.U.; Shah, A.J.; Connor, J.; Jabeen, Q. Blood pressure lowering effect of olive is mediated through calcium channel blockade. Int. J. Food Sci. Nutr., 2005, 56(8), 613-20.
166. Owen, R.W.; Giacosa, A.; Hull, W.E.; Haubner, R.; Wurtele, G.; Spiegelhalder, B.; Bartsch, H. Olive-oil consumption and health: the possible role of antioxidants. Lancet Oncol., 2000, 1, 107-12.
167. Tuck, K.L.; Hayball, P.J. Major phenolic compounds in olive oil: metabolism and health effects. J. Nutr. Biochem., 2002, 13(11), 636-644.
168. Owen, R.W.; Mier, W.; Giacosa, A.; Hull, W.E.; Spiegelhalder, B.; Bartsch, H. Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignansand squalene. Food. Chem. Toxicol., 2000, 38(8), 647-59.
169. Visioli, F.; Poli, A.; Gall, C. Antioxidant and other biological activities of phenols from olives and olive oil. Med. Res. Rev., 2002, 22(1), 65-75.
170. Perona, J.S.; Cabello-Moruno, R.; Ruiz-Gutierrez, V. The role of virgin olive oil components in the modulation of endothelial function. J. Nutr. BioChem., 2006, 17(7), 429-45.
171. Williams, R.J.; Spencer, J.P.; Rice-Evans, C. Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med., 2004, 36(7), 838-49.
172. Mattson, M.P.; Kroemer, G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med., 2003, 9(5),196-205.
173. Mandel, S.; Youdim, M.B. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic. Biol. Med., 2004, 37(3), 304-17.
174. Soobrattee, M.A.; Neergheen, V.S.; Luximon-Ramma, A.; Aruoma, O.I.; Bahorun, T. Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat. Res., 2005, 579(1-2), 200-13.
175. Ariga, T.; Jarvis, W.D.; Yu, R.K. Role of sphingolipid-mediated cell death in neurodegenerative diseases. J. Lipid. Res., 1998, 39(1), 1-16.
176. Bagchi, D.; Sen, C.K.; Ray, S.D.; Das, D.K.; Bagchi, M.; Preuss, H.G.;Vinson, J.A. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat. Res., 2003, 523-524, 87-97.
177. Quiles, J.L.; Farquharson, A.J.; Simpson, D.K.; Grant, I.; Wahle, K.W. Olive oil phenolics: effects on DNA oxidation and redox enzyme mRNA in prostate cells. Br. J. Nutr., 2002, 88(3), 225-34.
178. Fabiani, R.; De Bartolomeo, A.; Rosignoli, P.; Servili, M.; Montedoro, G.F.; Morozzi, G. Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur. J. Cancer Prev., 2002, 11(4), 351-8
179. Harwood J.L; Yaqoob P. Nutritional and health aspects of olive oil. Eur. J. Lipid. Sci. Technol., 2002, 104(9-10), 685-69
180. Gill, C.I.; Boyd, A.; McDermott, E.; McCann, M.; Servili, M.; Selvaggini, R.; Taticchi, A.; Esposto, S.; Montedoro, G.; McGlynn, H.; Rowland, I. Potential anti-cancer effects of virgin olive oil phenols on colorectal carcinogenesis models in vitro. Int. J. Cancer, 2005, 117(1), 1-7.
181. Solanas, M.; Hurtado, A.; Costa, I.; Moral, R.; Menéndez, J.A.; Colomer, R.; Escrich, E. Effects of a high olive oil diet on the clinical behavior and histopathological features of rat DMBAinduced mammary tumors compared with a high corn oil diet. Int. J. Oncol. 2002, 21(4), 745-53.
182. Costa, I.; Moral, R.; Solanas, M.; Escrich, E. High-fat corn oil diet promotes the development of high histologic grade rat DMBA-induced mammary adenocarcinomas, while high olive oil diet does not. Breast Cancer Res. Treat., 2004, 86(3), 225-35.
183. Newmark, H.L. Squalene, olive oil, and cancer risk: a review and hypothesis. Cancer Epidemiol. Biomarkers. Prev., 1997, 6(12), 1101-3.
184. Llor, X.; Pons, E.; Roca, A.; Alvarez, M.; Mane, J.; Fernandez-BanaRes., F.; Gassull, M.A. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin. Nutr., 2003, 22(1), 71-9.
185. Menendez, J.A.; Papadimitropoulou, A.; Vellon, L.; Lupu, R. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells. Eur. J. Cancer, 2006, 42(15), 2425-32.
186. Awade, A.C.; Cleuziat, P.; Gonzales, T.; Robert-Baudouy, J. Pyrrolidone carboxyl peptidase (Pcp): an enzyme that removes pyroglutamic acid (pGlu) from pGlu-peptides and pGlu-proteins. Proteins, 1994, 20(1), 34-51.
187. Topper, Y.J.; Sankaran, L.; Chomczynski, P.; Prosser, C.; Qasba, P. Three stages of responsiveness to hormones in the mammary cell. Ann. N. Y. Acad. Sci., 1986, 464, 1-10.
188. Abramovitch, S.; Werner, H. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGFIR gene. Horm. Metab. Res., 2003, 35(11-12), 758-62.
189. Seeger, H.; Wallwiener, D.; Mueck, A.O. Influence of stromaderived growth factors on the estradiol-stimulated proliferation of human breast cancer cells. Eur. J. Gynaecol. Oncol., 2004, 25, 175-7.
190. Russo, J.; Hu, Y.F.; Yang, X.; Russo, I.H. Developmental, cellular, and molecular basis of human breast cancer. J. Natl. Cancer Inst. Monogr., 2000, (27), 17-37.
191. Marshall, J.C.; Kelch, R.P. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N. Engl. J. Med., 1986, 315(23), 1459-68.
192. Carrera, M.P.; Ramirez-Exposito, M.J.; Valenzuela, M.T.; Garcia, M.J.; Mayas, M.D.; Arias de Saavedra, J.M.; Sanchez, R.; Perez, M.C.; Martinez-Martos, J.M. Pyrrolidon carboxypeptidase activities in the hypothalamus-pituitary-thyroid and hypothalamuspituitary-ovary axes of rats with mammary gland cancer induced by N-methyl nitrosourea. Horm. Metab. Res., 2005, 37(2), 74-8.
193. Carrera, M.P.; Ramirez-Exposito, M.J.; Valenzuela, M.T.; Garcia, M.J.; Mayas, M.D.; Martinez-Martos, J.M Serum pyrrolidone carboxypeptidase activity in N-methyl-nitrosourea induced rat breast cancer. Horm. Metab. Res., 2003, 35(8), 502-5.
194. Martinez, J.M.; Prieto, I.; Ramirez, M.J.; Cueva, C.; Alba, F.; Ramirez, M. Aminopeptidase activities in breast cancer tissue. Clin. Chem., 1999, 45(10), 1797-802.
195. Varona, A.; Blanco, L.; Lopez, J.I.; Gil, J.; Agirregoitia, E.; Irazusta, J.; Larrinaga, G. Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am. J. Physiol. Renal. Physiol., 2007, 292(2), F780-8.
196. Nanus, D.M.; Bogenrieder, T.; Papandreou, C.N.; Finstad, C.L.; Lee, A.; Vlamis, V.; Motzer, R.J.; Bander, N.H;, Albino, A.P.; Reuter, V.E. Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int. J. Oncol., 1998, 13(2), 261-7.
197. Smal, M.A.; Dong, Z.; Cheung, H.T.; Asano, Y.; Escoffier, L.; Costello, M.; Tattersall, M.H. Activation and cytotoxicity of 2-alpha-aminoacyl prodrugs of methotrexate. Biochem. Pharmacol., 1995, 49(4), 567-74.
198. Juillerat-Jeanneret, L.; Lohm, S.; Hamou, M.F.; Pinet, F. Regulation of aminopeptidase A in human brain tumor vasculature: evidence for a role of transforming growth factor-beta. Lab. Invest., 2000, 80(6), 973-80.
199. Fernandez, L.A.; Twickler, J.; Mead, A. Neovascularization produced by angiotensin II. J. Lab. Clin. Med., 1985, 105(2), 141-5.
200. Le Noble, F.A.; Hekking, J.W.; Van Straaten, H.W.; Slaaf, D.W.; Struyker Boudier, H.A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol., 1991, 195(2), 305-6.
201. Andrade, S.P.; Cardoso, C.C.; Machado, R.D.; Beraldo, W.T. Angiotensin-II-induced angiogenesis in sponge implants in mice. Int. J. Microcirc. Clin. Exp., 1996, 16(6), 302-7.
202. Hu, D.E.; Hiley, C.R.; Fan, T.P. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br. J. Pharmacol., 1996, 117(3), 545-551.
203. Walsh, D.A.; Hu, D.E.; Wharton, J.; Catravas, J.D.; Blake, D.R.; Fan, T.P. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat subcutaneous sponge granuloma. Br. J. Pharmacol., 1997, 120(7), 1302-11.
204. Wilk, S.; Wilk, E.; Magnusson, R.P. Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase. J. Biol. Chem. 1998, 273(26), 15961-70.
205. Ramirez-Exposito, M.J., Martinez, J.M., Prieto, I., Alba, F. & Ramirez, M Comparative distribution of glutamyl and aspartyl aminopeptidase activities in mouse organs. Horm. Metab. Res., 2000, 32(5), 161-3.
206. Ramirez-Exposito, M.J.; Martinez-Martos, J.M.; Mayas, M.D.; Garcia, M.J.; Prieto, I.; Arechaga, G.; Ramirez, M. Oleate, linoleate and cholesterol differently modify aspartyl- and glutamylaminopeptidase activities in primary cultures of rat astrocytes. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 2001, 128(1), 113-8.
207. Mayas, M.D.; Ramirez-Exposito, M.J.; Garcia, M.J.; Ramirez, M.; Martinez-Martos, J.M. Ethanol modifies differently aspartyl- and glutamyl-aminopeptidase activities in mouse frontal cortex synaptosomes. Brain Res. Bull., 2002, 57(2), 195-203.
208. Ardaillou, R.; Chansel, D. Synthesis and effects of active fragments of angiotensin II. Kidney Int., 1997, 52(6), 1458-68.
209. Ward, P.E.; Benter, I.F.; Dick, L.; Wilk, S. Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M. Biochem. Pharmacol., 1990, 40(8), 1725-32.
210. Beynon, R.J.; Bond, J.S. Piroteolytic. Enzymes, 2nd ed. Beynon & Bonds: Oxford University Press, 2001.
211. Dixon, J.; Kaklamanis, L.; Turley, H.; Hickson, I.D.; Leek, R.D.; Harris, A.L.; Gatter, K.C. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J. Clin. Pathol., 1994, 47(1), 43-7.
212. Stange, T.; Kettmann, U.; Holzhausen, H.J. Immunoelectron microscopic single and double labelling of aminopeptidase N (CD 13) and dipeptidyl peptidase IV (CD 26). Acta Histochem., 1996, 98(3), 323-31.
213. Kehlen, A.; Egbert, I.; Thiele, K.; Fischer, K.; Riemann, D.; Langner, J. Increased expression of interleukin-8 and aminopeptidase N by cell-cell contact: interleukin-8 is resistant to degradation by aminopeptidase N/CD13. Eur. Cytokine Netw., 2001, 12(2), 316-24.
214. Shipp, M.A.; Look, A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood, 1993, 82(4), 1052-70.
215. Saiki, I.; Fujii, H.; Yoneda, J.; Abe, F.; Nakajima, M.; Tsuruo, T.; Azuma, I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer, 1993, 54(1), 137-43.
216. Riemann, D.; Kehlen, A.; Langner, J. CD13 - not just a marker in leukemia typing. Immunol. Today, 1999 20(2), 83-8.
217. Bhagwat, S.V.; Lahdenranta, J.; Giordano, R.; Arap, W.; Pasqualini, R.; Shapiro, L.H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 2001, 97(3), 652-9.
218. Kehlen, A.; Gohring, B.; Langner, J.; Riemann, D. Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators. Clin. Exp. Immunol., 1998, 111(2), 435-41.
219. Hashida, H.; Takabayashi, A.; Kanai, M.; Adachi, M.; Kondo, K.; Kohno, N.; Yamaoka, Y.; Miyake, M. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology, 2002, 122(2), 376-86.
220. Terauchi, M.; Kajiyama, H.; Shibata, K.; Ino, K.; Nawa, A.; Mizutani, S.; Kikkawa, F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer, 2007 27(7), 140.
221. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60(3), 722-7.
222. Petrovic, N.; Bhagwat, S.V.; Ratzan, W.J.; Ostrowski, M.C.; Shapiro, L.H. CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells. J. Biol. Chem., 2003, 278(49), 49358-68.
223. Mahoney, K.M.; Petrovic, N.; Schacke, W.; Shapiro, L.H. CD13/APN transcription is regulated by the proto-oncogene c-Maf via. an atypical response element. Gene, 2007, 403(1-2), 178-87.
224. Dlakic, M.; Grinberg, A.V.; Leonard, D.A.; Kerppola, T.K. DNA sequence-dependent folding determines the divergence in binding specificities between Maf and other bZIP proteins. EMBO. J., 2001, 20(4), 828-840.
225. Favaloro, E.J.; Browning, T.; Nandurkar, H. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. Clin. Chim. Acta, 1993, 220(1), 81-90.
226. van Hensbergen, Y.; Broxterman, H.J.; Hanemaaijer, R.; Jorna, A.S.; van Lent, N.A.; Verheul, H.M.; Pinedo, H.M.; Hoekman, K. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res., 2002, 8(12), 3747-54.
227. Bauvois, B.; Dauzonne, D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med. Res. Rev., 2006, 26(1), 88-130.
228. Grujic, M.; Renko, M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett., 2002, 182(2), 113-9.
229. Surowiak, P.; Drag, M.; Materna, V.; Suchocki, S.; Grzywa, R.; Spaczynski, M.; Dietel, M.; Oleksyszyn, J.; Zabel, M.; Lage, H. Expression of aminopeptidase N/CD13 in human ovarian cancers. Int. J. Gynecol. Cancer, 2006, 16(5), 1783-8.
230. Suganuma, T.; Ino, K.; Shibata, K.; Nomura, S.; Kajiyama, H.; Kikkawa, F.; Tsuruoka, N.; Mizutani, S. Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab. Invest., 2004, 84(5), 639-48.
231. Fujimura, H.; Ino, K.; Nagasaka, T.; Nakashima, N.; Nakazato, H.; Kikkawa, F.; Mizutani, S. Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression. Oncology, 2000, 58(4), 342-52.
232. Carrera, M.P.; Ramirez-Exposito, M.J.; Valenzuela, M.T.; Garcia, M.J.; Mayas, M.D.; Martinez-Martos, J.M. Glutamyl- but not aspartyl-aminopeptidase activity is modified in serum of N-methyl nitrosourea-induced rat mammary tumours. Anticancer Res., 2004, 24(2B), 801-5.
233. Saavedra, J.M. Brain and pituitary angiotensin. Endocr. Rev., 1992, 13(2), 329-80.
234. Ganong, W.F. Blood, pituitary, and brain renin-angiotensin systems and regulation of secretion of anterior pituitary gland. Front Neuroendocrinol., 1993, 14(3), 233-49.
235. Schlingemann, R.O.; Oosterwijk, E.; Wesseling, P.; Rietveld, F.J.; Ruiter, D.J. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J. Pathol., 1996, 179(4), 436-42.
236. De Paepe, B.; Verstraeten, V.M.; De Potter, C.R.; Bullock, G.R. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem. Cell. Biol., 2002, 117(1), 13-9.